“`html
Nordicus Partners Corporation (OTCQB: NORD), a business accelerator focused on Nordic and U.S. life sciences companies, announced significant changes to its Board of Directors. The company expanded its board from three to five members, with Henrik Keller resigning and three new directors joining: Torben Jensen (major shareholder), Kim T. Mücke (accounting expert and future Audit Committee chairman), and Andrew J. Ritter (experienced pharma CEO).
The new appointments align with Nordicus’s strategy to acquire majority stakes in Nordic and U.S.-based life sciences companies, bringing expertise in funding, accounting, and strategic relationships.
Nordicus Partners Corporation (OTCQB: NORD), un acceleratore d’impresa focalizzato sulle aziende nordiche e statunitensi nel settore delle scienze della vita, ha annunciato importanti cambiamenti nel suo Consiglio di Amministrazione. La società ha ampliato il consiglio da tre a cinque membri, con le dimissioni di Henrik Keller e l’ingresso di tre nuovi direttori: Torben Jensen (azionista di maggioranza), Kim T. Mücke (esperto contabile e futuro presidente del Comitato di Revisione) e Andrew J. Ritter (CEO esperto nel settore farmaceutico).
Le nuove nomine sono in linea con la strategia di Nordicus di acquisire partecipazioni di maggioranza in aziende di scienze della vita con sede nei Paesi nordici e negli Stati Uniti, apportando competenze in finanziamenti, contabilità e relazioni strategiche.
Nordicus Partners Corporation (OTCQB: NORD), un acelerador de negocios enfocado en empresas de ciencias de la vida de los países nórdicos y Estados Unidos, anunció cambios significativos en su Junta Directiva. La compañía amplió su junta de tres a cinco miembros, con la renuncia de Henrik Keller y la incorporación de tres nuevos directores: Torben Jensen (accionista mayoritario), Kim T. Mücke (experto en contabilidad y futuro presidente del Comité de Auditoría) y Andrew J. Ritter (CEO experimentado en la industria farmacéutica).
Las nuevas designaciones están alineadas con la estrategia de Nordicus de adquirir participaciones mayoritarias en empresas de ciencias de la vida con sede en los países nórdicos y Estados Unidos, aportando experiencia en financiamiento, contabilidad y relaciones estratégicas.
Nordicus Partners Corporation (OTCQB: NORD)는 북유럽 및 미국 생명과학 기업에 중점을 둔 비즈니스 액셀러레이터로서 이사회의 중대한 변화를 발표했습니다. 회사는 이사회를 3명에서 5명으로 확대했으며, 헨릭 켈러가 사임하고 세 명의 신규 이사가 합류했습니다: 토르벤 옌센 (주요 주주), 킴 T. 뮈케 (회계 전문가이자 향후 감사위원회 의장), 그리고 앤드류 J. 리터 (경험 많은 제약 CEO)입니다.
이번 신규 임명은 북유럽 및 미국에 기반을 둔 생명과학 기업의 과반 지분 인수를 목표로 하는 Nordicus의 전략과 부합하며, 자금 조달, 회계 및 전략적 관계에 대한 전문성을 제공합니다.
Nordicus Partners Corporation (OTCQB : NORD), un accélérateur d’entreprises axé sur les sociétés des sciences de la vie nordiques et américaines, a annoncé des changements importants au sein de son conseil d’administration. La société a élargi son conseil de trois à cinq membres, avec la démission de Henrik Keller et l’arrivée de trois nouveaux administrateurs : Torben Jensen (actionnaire majoritaire), Kim T. Mücke (expert en comptabilité et futur président du comité d’audit) et Andrew J. Ritter (PDG expérimenté dans le secteur pharmaceutique).
Ces nouvelles nominations s’alignent sur la stratégie de Nordicus visant à acquérir des participations majoritaires dans des entreprises des sciences de la vie basées en Scandinavie et aux États-Unis, apportant une expertise en financement, comptabilité et relations stratégiques.
Nordicus Partners Corporation (OTCQB: NORD), ein Business Accelerator mit Fokus auf nordische und US-amerikanische Life-Sciences-Unternehmen, gab bedeutende Veränderungen in seinem Vorstand bekannt. Das Unternehmen erweiterte seinen Vorstand von drei auf fünf Mitglieder, wobei Henrik Keller zurücktrat und drei neue Direktoren hinzukamen: Torben Jensen (Mehrheitsaktionär), Kim T. Mücke (Bilanzexperte und zukünftiger Vorsitzender des Prüfungsausschusses) sowie Andrew J. Ritter (erfahrener Pharma-CEO).
Die neuen Ernennungen stehen im Einklang mit der Strategie von Nordicus, Mehrheitsbeteiligungen an nordischen und US-amerikanischen Life-Sciences-Unternehmen zu erwerben und bringen Expertise in Finanzierung, Buchhaltung und strategischen Beziehungen mit.
Positive
- Board expansion from 3 to 5 members indicates corporate governance enhancement
- Addition of experienced directors with complementary expertise in funding, accounting, and pharma industry
- New director Torben Jensen is already a major shareholder, showing alignment with investor interests
- Addition of experienced public company CEO strengthens strategic acquisition capabilities
Negative
- Resignation of board member Henrik Keller creates potential continuity gap
- Significant board restructuring may temporarily impact decision-making processes
08/07/2025 – 09:50 AM
BEVERLY HILLS, CA – August 7, 2025 – Nordicus Partners Corporation (OTCQB: NORD), a business accelerator laser-focused on bridging the gap between Nordic innovation and the lucrative U.S. life sciences market, today announced a strategic shakeup at the board level. In a move signaling a renewed commitment to expansion, the company increased its Board of Directors from three to five seats. This follows the resignation of Henrik Keller, paving the way for the appointments of Torben Jensen, Kim T. Mücke, and Andrew J. Ritter.
Jensen, already a significant shareholder, brings a wealth of experience in project funding. Mücke, a seasoned accounting expert slated to chair the Audit Committee, adds financial rigor to the team. Rounding out the trio is Ritter, a pharma CEO with a proven track record of steering public companies through the complexities of the pharmaceutical landscape.
“We appreciate Henrik Keller’s contributions and are thrilled to welcome Torben, Kim, and Andrew,” stated Henrik Rouf, CEO of Nordicus. “Their collective expertise in funding, accounting, corporate finance, and strategic partnerships, particularly within the U.S. market, will be instrumental as we execute our strategy of acquiring controlling interests in promising Nordic and U.S. life sciences companies.” This move underscores Nordicus’ ambition to identify and nurture high-potential companies, ultimately unlocking value for shareholders.
Meet the New Directors:
Torben Jensen (60): A seasoned financial veteran with over 35 years of experience, Jensen has a history of developing and funding ventures across diverse sectors, including real estate, energy, and life sciences. His prior experience as CEO and Chairman of two Nasdaq-listed companies, coupled with his recent role as Senior Partner at GK Partners ApS, positions him as a crucial asset for Nordicus’ funding initiatives.
Kim T. Mücke: A Danish state-authorized public accountant with a master’s degree in Auditing and Accounting from the Copenhagen Business School. Mücke’s impressive resume includes a lengthy tenure as a partner with Deloitte Denmark, along with his recent role as Head of Corporate Clients for BDO Denmark. As an independent advisor specializing in financial reporting, risk management, and corporate governance, Mücke’s appointment signals Nordicus’ commitment to best-in-class financial practices.
Andrew J. Ritter: A proven leader in the pharmaceutical space, Ritter brings a strong entrepreneurial spirit and deep understanding of the healthcare industry. He currently serves as CEO of Cairns Health, an AI-powered remote care innovator. Previously, he was the CEO of Docbot and founder of Ritter Pharmaceuticals. His experience navigating the complexities of the pharmaceutical market will be invaluable as Nordicus seeks to establish strategic partnerships and potential acquisitions.
About Nordicus Partners Corporation
Nordicus Partners Corporation stands as the only U.S. publicly traded business accelerator and holding company with a specific focus on Nordic life sciences companies. Leveraging decades of combined management experience, Nordicus specializes in providing a gateway for innovative Nordic companies to thrive in the U.S. market. Nordicus boasts a unique portfolio, including 100% ownership of Orocidin A/S, a preclinical biotech company developing cutting-edge therapies for periodontitis, and 100% of Bio-Convert A/S, a pioneering biotech firm revolutionizing the treatment of oral leukoplakia. More information can be found at www.nordicuspartners.com, and on LinkedIn, X, Threads and BlueSky.
Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could impact the company’s performance include, but are not limited to, the success of its acquisition strategy, the performance of its portfolio companies, and the overall economic climate. Nordicus Partners Corporation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.
For media inquiries, please contact:
FAQ
Who are the new board members appointed to Nordicus Partners (OTCQB: NORD)?
The three new board members are Torben Jensen (major shareholder), Kim T. Mücke (future Audit Committee chairman), and Andrew J. Ritter (experienced pharma CEO).
Why did Nordicus Partners expand its board of directors in August 2025?
Nordicus expanded its board from three to five members to enhance corporate governance and bring in expertise in funding, accounting, and strategic relationships for its life sciences acquisition strategy.
What is Nordicus Partners’ (NORD) business focus?
Nordicus Partners is a business accelerator and holding company that helps Nordic and U.S. life sciences companies establish themselves in the U.S. market, with a focus on acquiring majority stakes in these companies.
Who replaced Henrik Keller on Nordicus Partners’ board?
Following Henrik Keller’s resignation, the board was expanded and filled by three new directors: Torben Jensen, Kim T. Mücke, and Andrew J. Ritter.
What experience do the new Nordicus (NORD) board members bring?
The new directors bring diverse expertise: Jensen is a major shareholder with funding experience, Mücke has extensive accounting industry experience, and Ritter brings public company CEO experience in the pharma sector.